Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nab-paclitaxel + S-1 vs XELOX in Stage III Gastric Cancer
NCT04135781Phase 3Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in gastric adenocarcinoma (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 3-year Disease-free Survival rate. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04135781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135781.